Emerging drugs for managing kidney disease in patients with diabetes

Bibliography

• Federation ID. IDF diabetes atlas. 4th edition. International Diabetes Federation, Brussels, Belgium; 2009
   Google Scholar
• Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26(3):917-32
   PubMed Web of Science ®Google Scholar
• Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341(15):1127-33
   PubMed Web of Science ®Google Scholar
• U. S. Renal Data System. USRDS 2004 annual data report: atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD, USA; 2004
   Google Scholar
• Groop PH, Thomas MC, Moran JL, The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58(7):1651-8
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010;53(11):2312-19
   PubMed Web of Science ®Google Scholar
• Stephenson JM, Kenny S, Stevens LK, Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular disease in diabetes. Diabet Med 1995;12(2):149-55
   PubMed Web of Science ®Google Scholar
• Adler AI, Stevens RJ, Manley SE, Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63(1):225-32
   PubMed Web of Science ®Google Scholar
• Dwyer JP, Parving HH, Hunsicker LG, Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND study. Cardiorenal Med 2012;2(1):1-10
   Google Scholar
• Zoungas S, de Galan BE, Ninomiya T, Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 2009;32(11):2068-74
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348(5):383-93
   PubMed Web of Science ®Google Scholar
• Horita Y, Taura K, Taguchi T, Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology (Carlton) 2006;11(5):462-6
   PubMed Web of Science ®Google Scholar
• Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007;3(9):486-92
   PubMedGoogle Scholar
• Schjoedt KJ, Andersen S, Rossing P, Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004;47(11):1936-9
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358(23):2433-46
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Reinhard H, Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009;32(10):1873-9
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24(5):1663-71
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367(23):2204-13
   PubMed Web of Science ®Google Scholar
• Smulders YM, van Eeden AE, Stehouwer CD, Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 1997;27(12):997-1002
   PubMed Web of Science ®Google Scholar
• Nagai T, Tomizawa T, Nakajima K, Mori M. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J Atheroscler Thromb 2000;7(2):91-6
   PubMedGoogle Scholar
• Park CW, Zhang Y, Zhang X, PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006;69(9):1511-17
   PubMed Web of Science ®Google Scholar
• Ren S, Xin C, Beck KF, PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochem Biophys Res Commun 2005;338(4):1818-24
   PubMed Web of Science ®Google Scholar
• Zhao X, Li LY. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol 2008;28(4):598-606
   PubMed Web of Science ®Google Scholar
• Ansquer JC, Foucher C, Rattier S, Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45(3):485-93
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1563-74
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375(9729):1875-84
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Stafylas PC, Georgianos PI, Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010;55(5):835-47
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170(14):1191-201
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Livingstone SJ, Looker HC, Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 2012;55(11):2929-37
   PubMed Web of Science ®Google Scholar
• Li YC, Kong J, Wei M, 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110(2):229-38
   PubMed Web of Science ®Google Scholar
• Porsti IH. Expanding targets of vitamin D receptor activation: downregulation of several RAS components in the kidney. Kidney Int 2008;74(11):1371-3
   PubMed Web of Science ®Google Scholar
• Rojas-Rivera J, De La Piedra C, Ramos A, The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 2010;25(9):2850-65
   PubMed Web of Science ®Google Scholar
• Freundlich M, Quiroz Y, Zhang Z, Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74(11):1394-402
   PubMed Web of Science ®Google Scholar
• Wu-Wong JR. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br J Pharmacol 2009;158(2):395-412
   PubMed Web of Science ®Google Scholar
• Zhang Z, Sun L, Wang Y, Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008;73(2):163-71
   PubMed Web of Science ®Google Scholar
• Tanaka H, Hamano T, Fujii N, The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone 2009;45(5):949-55
   PubMed Web of Science ®Google Scholar
• Kim MJ, Frankel AH, Donaldson M, Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 2011;80(8):851-60
   PubMed Web of Science ®Google Scholar
• Alborzi P, Patel NA, Peterson C, Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008;52(2):249-55
   PubMed Web of Science ®Google Scholar
• Agarwal R, Acharya M, Tian J, Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005;68(6):2823-8
   PubMed Web of Science ®Google Scholar
• Fishbane S, Chittineni H, Packman M, Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009;54(4):647-52
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Agarwal R, Amdahl M, Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376(9752):1543-51
   PubMed Web of Science ®Google Scholar
• Witham MD, Dove FJ, Dryburgh M, The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2010;53(10):2112-19
   PubMed Web of Science ®Google Scholar
• Burns WC, Thomas MC. The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology. Expert Rev Mol Med 2010;12:e17
   PubMed Web of Science ®Google Scholar
• Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res 2008;25(10):2447-61
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Ghiassi M, Aakre M, TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc Natl Acad Sci USA 2003;100(26):15548-53
   PubMed Web of Science ®Google Scholar
• Guo X, Wang L, Chen B, ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability. Am J Physiol Heart Circ Physiol 2009;297(1):H238-46
   PubMed Web of Science ®Google Scholar
• Zimering MB, Pan Z. Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. J Clin Endocrinol Metab 2009;94(6):2171-7
   PubMed Web of Science ®Google Scholar
• Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999;274(31):21926-31
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009;54(5):810-19
   PubMed Web of Science ®Google Scholar
• Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006;145(2):117-24
   PubMed Web of Science ®Google Scholar
• Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006;290(3):C661-8
   PubMed Web of Science ®Google Scholar
• Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98(3):322-34
   PubMed Web of Science ®Google Scholar
• Patel RA, Forinash KD, Pireddu R, RKI-1447 is a potent inhibitor of the rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res 2012;72(19):5025-34
   PubMed Web of Science ®Google Scholar
• Lohn M, Plettenburg O, Ivashchenko Y, Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 2009;54(3):676-83
   PubMed Web of Science ®Google Scholar
• Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995;38(4):387-94
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414(6865):813-20
   PubMed Web of Science ®Google Scholar
• Soulis-Liparota T, Cooper M, Papazoglou D, Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991;40(10):1328-34
   PubMed Web of Science ®Google Scholar
• Bolton WK, Cattran DC, Williams ME, Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24(1):32-40
   PubMed Web of Science ®Google Scholar
• Wendt TM, Tanji N, Guo J, RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162(4):1123-37
   PubMed Web of Science ®Google Scholar
• La Selva M, Beltramo E, Pagnozzi F, Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 1996;39(11):1263-8
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 2005;1(3):287-98
   PubMedGoogle Scholar
• Riaz S, Skinner V, Srai SK. Effect of high dose thiamine on the levels of urinary protein biomarkers in diabetes mellitus type 2. J Pharm Biomed Anal 2011;54(4):817-25
   PubMed Web of Science ®Google Scholar
• Rabbani N, Alam SS, Riaz S, High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia 2009;52(2):208-12
   PubMed Web of Science ®Google Scholar
• Alkhalaf A, Klooster A, van Oeveren W, A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010;33(7):1598-601
   PubMed Web of Science ®Google Scholar
• House AA, Eliasziw M, Cattran DC, Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010;303(16):1603-9
   PubMed Web of Science ®Google Scholar
• Degenhardt TP, Alderson NL, Arrington DD, Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61(3):939-50
   PubMed Web of Science ®Google Scholar
• Alderson NL, Chachich ME, Youssef NN, The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 2003;63(6):2123-33
   PubMed Web of Science ®Google Scholar
• Williams ME, Bolton WK, Khalifah RG, Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007;27(6):605-14
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Greene T, Spitalewiz S, Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23(1):131-6
   PubMed Web of Science ®Google Scholar
• Cai W, He JC, Zhu L, High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004;110(3):285-91
   PubMed Web of Science ®Google Scholar
• Sanaka T, Akizawa T, Koide K, Koshikawa S. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy. Ther Apher Dial 2004;8(3):232-40
   PubMed Web of Science ®Google Scholar
• Hayashino Y, Fukuhara S, Akizawa T, Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease. Diabetes Res Clin Pract 2010;90(2):154-9
   PubMed Web of Science ®Google Scholar
• Konishi K, Nakano S, Tsuda S, AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Res Clin Pract 2008;81(3):310-15
   PubMed Web of Science ®Google Scholar
• Hatakeyama S, Yamamoto H, Okamoto A, Effect of an oral adsorbent, AST-120, on dialysis initiation and survival in patients with Chronic Kidney disease. Int J Nephrol 2012;2012:376128
   PubMedGoogle Scholar
• Morcos M, Sayed AA, Bierhaus A, Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002;51(12):3532-44
   PubMed Web of Science ®Google Scholar
• Reiniger N, Lau K, McCalla D, Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 2010;59(8):2043-54
   PubMed Web of Science ®Google Scholar
• Kanwar YS, Sun L, Xie P, A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 2011;6:395-423
   PubMed Web of Science ®Google Scholar
• Phillips AO, Steadman R. Diabetic nephropathy: the central role of renal proximal tubular cells in tubulointerstitial injury. Histol Histopathol 2002;17(1):247-52
   PubMed Web of Science ®Google Scholar
• Okada H, Kikuta T, Kobayashi T, Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 2005;16(1):133-43
   PubMed Web of Science ®Google Scholar
• Baelde HJ, Eikmans M, Lappin D, Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 2007;71(7):637-45
   PubMed Web of Science ®Google Scholar
• Nishida T, Kondo S, Maeda A, CCN family 2/connective tissue growth factor (CCN2/CTGF) regulates the expression of Vegf through Hif-1alpha expression in a chondrocytic cell line, HCS-2/8, under hypoxic condition. Bone 2009;44(1):24-31
   PubMed Web of Science ®Google Scholar
• Zhang M, Lv XY, Li J, The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res 2008;2008:704045
   PubMed Web of Science ®Google Scholar
• Furumatsu T, Kanazawa T, Miyake Y, Mechanical stretch increases Smad3-dependent CCN2 expression in inner meniscus cells. J Orthop Res 2012;30(11):1738-45
   PubMed Web of Science ®Google Scholar
• Nishida T, Maeda A, Kubota S, Takigawa M. Role of mechanical-stress inducible protein Hcs24/CTGF/CCN2 in cartilage growth and regeneration: mechanical stress induces expression of Hcs24/CTGF/CCN2 in a human chondrocytic cell line HCS-2/8, rabbit costal chondrocytes and meniscus tissue cells. Biorheology 2008;45(3-4):289-99
   PubMed Web of Science ®Google Scholar
• Burns WC, Kantharidis P, Thomas MC. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs 2007;185(1-3):222-31
   PubMed Web of Science ®Google Scholar
• Burns WC, Twigg SM, Forbes JM, Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006;17(9):2484-94
   PubMed Web of Science ®Google Scholar
• Ito Y, Aten J, Bende RJ, Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998;53(4):853-61
   PubMed Web of Science ®Google Scholar
• Ito Y, Aten J, Nguyen TQ, Involvement of connective tissue growth factor in human and experimental hypertensive nephrosclerosis. Nephron Exp Nephrol 2011;117(1):e9-20
   PubMed Web of Science ®Google Scholar
• Roestenberg P, van Nieuwenhoven FA, Joles JA, Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2006;290(6):1344-54
   Google Scholar
• Denton CP, Abraham DJ. Transforming growth factor-[beta] and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13(6):505
   PubMed Web of Science ®Google Scholar
• Dendooven A, Gerritsen KG, Nguyen TQ, Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers 2011;16(4):289-301
   PubMed Web of Science ®Google Scholar
• Goldschmeding R, Aten J, Ito Y, Connective tissue growth factor: just another factor in renal fibrosis? Nephrol Dial Transplant 2000;15(3):296-9
   PubMed Web of Science ®Google Scholar
• Sanchez-Lopez E, Rayego S, Rodrigues-Diez R, CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB. J Am Soc Nephrol 2009;20(7):1513-26
   PubMed Web of Science ®Google Scholar
• Twigg SM, Cooper ME. The time has come to target connective tissue growth factor in diabetic complications. Diabetologia 2004;47(6):965-8
   PubMed Web of Science ®Google Scholar
• Adler SG, Schwartz S, Williams ME, Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. CJASN 2010;5(8):1420-8
   PubMed Web of Science ®Google Scholar
• Lassila M, Jandeleit-Dahm K, Seah KK, Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005;16(2):363-73
   PubMed Web of Science ®Google Scholar
• Mogyorosi A, Ziyadeh FN. What is the role of decorin in diabetic kidney disease? Nephrol Dial Transplant 1999;14(5):1078-81
   PubMed Web of Science ®Google Scholar
• Hawthorne T, Giot L, Blake L, A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther 2008;46(5):236-44
   PubMed Web of Science ®Google Scholar
• Cho ME, Smith DC, Branton MH, Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007;2(5):906-13
   PubMed Web of Science ®Google Scholar
• Soma J, Sato K, Saito H, Tsuchiya Y. Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 2006;21(10):2795-9
   PubMed Web of Science ®Google Scholar
• Soma J, Sugawara T, Huang YD, Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002;92(3):693-8
   PubMed Web of Science ®Google Scholar
• Williams JM, Zhang J, North P, Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am J Physiol Renal Physiol 2011;300(4):F983-98
   PubMed Web of Science ®Google Scholar
• Aggarwal HK, Jain D, Talapatra P, Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy. Ren Fail 2010;32(8):941-6
   PubMed Web of Science ®Google Scholar
• Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 2001;104(1):16-18
   PubMed Web of Science ®Google Scholar
• Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 2001;19(12):2191-6
   PubMed Web of Science ®Google Scholar
• Langham RG, Kelly DJ, Gow RM, Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 2004;44(5):826-31
   PubMed Web of Science ®Google Scholar
• Totsune K, Takahashi K, Arihara Z, Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004;25(10):1809-14
   PubMed Web of Science ®Google Scholar
• Clozel M, Binkert C, Birker-Robaczewska M, Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System. J Pharmacol Exp Ther 2004;311(1):204-12
   PubMed Web of Science ®Google Scholar
• Sidharta PN, Wagner FD, Bohnemeier H, Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 2006;80(3):246-56
   PubMed Web of Science ®Google Scholar
• Vogt L, Chiurchiu C, Chadha-Boreham H, Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. Hypertension 2010;55(5):1206-9
   PubMed Web of Science ®Google Scholar
• Behm DJ, Aiyar NV, Olzinski AR, GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo. Br J Pharmacol 2010;161(1):207-28
   PubMed Web of Science ®Google Scholar
• Meier M, Park JK, Overheu D, Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes 2007;56(2):346-54
   PubMed Web of Science ®Google Scholar
• Koya D, Haneda M, Nakagawa H, Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000;14(3):439-47
   PubMed Web of Science ®Google Scholar
• Ishii H, Jirousek MR, Koya D, Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272(5262):728-31
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Bakris GL, Toto RD, The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005;28(11):2686-90
   PubMed Web of Science ®Google Scholar
• Tuttle KR, McGill JB, Haney DJ, Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007;2(4):631-6
   PubMed Web of Science ®Google Scholar
• Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008;57(6):1446-54
   PubMed Web of Science ®Google Scholar
• Asaba K, Tojo A, Onozato ML, Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 2005;67(5):1890-8
   PubMed Web of Science ®Google Scholar
• Sedeek M, Gutsol A, Montezano AC, Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond) 2013;124(3):191-202
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5(8):1388-93
   PubMed Web of Science ®Google Scholar
• Momeni A, Shahidi S, Seirafian S, Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis 2010;4(2):128-32
   PubMed Web of Science ®Google Scholar
• Abdellatif AA, Elkhalili N. Management of gouty arthritis in patients with Chronic Kidney disease. Am J Ther 2012; [Epub ahead of print]
   Google Scholar
• Morcos M, Borcea V, Isermann B, Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract 2001;52(3):175-83
   PubMed Web of Science ®Google Scholar
• Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by pycnogenol supplementation. Nutr Res 2008;28(5):315-20
   PubMed Web of Science ®Google Scholar
• Kar P, Laight D, Rooprai HK, Effects of grape seed extract in type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity. Diabet Med 2009;26(5):526-31
   PubMed Web of Science ®Google Scholar
• Kadhim HM, Ismail SH, Hussein KI, Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. J Pineal Res 2006;41(2):189-93
   PubMed Web of Science ®Google Scholar
• Farvid MS, Jalali M, Siassi F, Hosseini M. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care 2005;28(10):2458-64
   PubMed Web of Science ®Google Scholar
• Lonn E, Yusuf S, Hoogwerf B, Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002;25(11):1919-27
   PubMed Web of Science ®Google Scholar
• Mann JF, Lonn EM, Yi Q, Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int 2004;65(4):1375-80
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Torita M, Yoshizawa M, Usuda R. Indication of vitamin E on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Metab 2001;27(5 Pt 1):611-12
   PubMed Web of Science ®Google Scholar
• Gaede P, Poulsen HE, Parving HH, Pedersen O. Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients. Diabet Med 2001;18(9):756-60
   PubMed Web of Science ®Google Scholar
• DeRubertis FR, Craven PA, Melhem MF. Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: effects of tempol. Metabolism 2007;56(9):1256-64
   PubMed Web of Science ®Google Scholar
• Xue M, Qian Q, Adaikalakoteswari A, Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 2008;57(10):2809-17
   PubMed Web of Science ®Google Scholar
• Zheng H, Whitman SA, Wu W, Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011;60(11):3055-66
   PubMed Web of Science ®Google Scholar
• Pergola PE, Raskin P, Toto RD, Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365(4):327-36
   PubMed Web of Science ®Google Scholar
• Pergola PE, Krauth M, Huff JW, Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 2010;33(5):469-76
   Web of Science ®Google Scholar
• Johnstone MT, Creager SJ, Scales KM, Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88(6):2510-16
   PubMed Web of Science ®Google Scholar
• Williams SB, Cusco JA, Roddy M-A, Impaired nitric oxide-mediated vasodilatation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996;27:567-74
   PubMed Web of Science ®Google Scholar
• Turnbull CM, Marcarino P, Sheldrake TA, A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages. J Inflamm (Lond) 2008;5:12
   PubMedGoogle Scholar
• Schuhmacher S, Oelze M, Bollmann F, Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes 2011;60(10):2608-16
   PubMed Web of Science ®Google Scholar
• Kuno Y, Iyoda M, Shibata T, Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. Br J Pharmacol 2011;162(6):1389-400
   PubMed Web of Science ®Google Scholar
• Grover-Paez F, Villegas Rivera G, Guillen Ortiz R. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res Clin Pract 2007;78(1):136-40
   PubMed Web of Science ®Google Scholar
• Onozato ML, Tojo A, Goto A, Fujita T. Effect of combination therapy with dipyridamole and quinapril in diabetic nephropathy. Diabetes Res Clin Pract 2003;59(2):83-92
   PubMed Web of Science ®Google Scholar
• Aizawa T, Suzuki S, Asawa T, Dipyridamole reduces urinary albumin excretion in diabetic patients with normo- or microalbuminuria. Clin Nephrol 1990;33(3):130-5
   PubMed Web of Science ®Google Scholar
• Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 2005;16(7):2119-26
   PubMed Web of Science ®Google Scholar
• Aminorroaya A, Janghorbani M, Rezvanian H, Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract 2005;99(3):c73-7
   PubMed Web of Science ®Google Scholar
• Shan D, Wu HM, Yuan QY, Pentoxifylline for diabetic kidney disease. Cochrane Database Syst Rev 2012;2:CD006800
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Muros M, Mora-Fernandez C, Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results. J Diabetes Complications 2011;25(5):314-19
   PubMed Web of Science ®Google Scholar
• Salmon AH, Ferguson JK, Burford JL, Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol 2012;23(8):1339-50
   PubMed Web of Science ®Google Scholar
• Salmon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability. J Pathol 2012;226(4):562-74
   PubMed Web of Science ®Google Scholar
• Gambaro G, Cavazzana AO, Luzi P, Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992;42(2):285-91
   PubMed Web of Science ®Google Scholar
• Achour A, Kacem M, Dibej K, One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol 2005;18(5):568-74
   PubMed Web of Science ®Google Scholar
• van der Pijl JW, van der Woude FJ, Geelhoed-Duijvestijn PH, Danaparoid sodium lowers proteinuria in diabetic nephropathy. J Am Soc Nephrol 1997;8(3):456-62
   PubMed Web of Science ®Google Scholar
• Gambaro G, Kinalska I, Oksa A, Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002;13(6):1615-25
   PubMedGoogle Scholar
• Sulikowska B, Olejniczak H, Muszynska M, Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrol 2006;26(6):621-8
   PubMed Web of Science ®Google Scholar
• Blouza S, Dakhli S, Abid H, Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol 2010;23(4):415-24
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Lewis JB, Greene T, Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis 2011;58(5):729-36
   PubMed Web of Science ®Google Scholar
• Packham DK, Wolfe R, Reutens AT, Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23(1):123-30
   PubMed Web of Science ®Google Scholar
• Gambaro G. Discounting the efficacy of sulodexide in diabetic nephropathy is premature. Am J Kidney Dis 2012;60(1):169-70
   PubMed Web of Science ®Google Scholar
• Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 2006;36(Suppl 3):78-88
   PubMed Web of Science ®Google Scholar
• Hocher B, Thone-Reineke C, Rohmeiss P, Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997;99(6):1380-9
   PubMed Web of Science ®Google Scholar
• De Mattia G, Cassone-Faldetta M, Bellini C, Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am J Hypertens 1998;11(8 Pt 1):983-8
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ebihara I, Fukui M, Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995;44(8):895-9
   PubMed Web of Science ®Google Scholar
• Dhein S, Hochreuther S, Aus Dem Spring C, Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. J Pharmacol Exp Ther 2000;293(2):351-9
   PubMed Web of Science ®Google Scholar
• Hocher B, Schwarz A, Reinbacher D, Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 2001;87(2):161-9
   PubMed Web of Science ®Google Scholar
• Sasser JM, Sullivan JC, Hobbs JL, Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007;18(1):143-54
   PubMed Web of Science ®Google Scholar
• Honing ML, Hijmering ML, Ballard DE, Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans. J Am Soc Nephrol 2000;11(8):1498-504
   PubMed Web of Science ®Google Scholar
• Kohan DE, Pritchett Y, Molitch M, Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011;22(4):763-72
   PubMed Web of Science ®Google Scholar
• Mann JF, Green D, Jamerson K, Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21(3):527-35
   PubMed Web of Science ®Google Scholar
• Wenzel RR, Littke T, Kuranoff S, Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20(3):655-64
   PubMed Web of Science ®Google Scholar
• Baltatu OC, Iliescu R, Zaugg CE, Antidiuretic effects of the endothelin receptor antagonist avosentan. Front Physiol 2012;3:103
   Google Scholar
• Navarro JF, Milena FJ, Mora C, Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int Suppl 2005(99):S98-102
   Google Scholar
• Navarro JF, Mora C, Muros M, Garcia J. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant 2006;21(12):3428-34
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Grigoropoulos V, Emfietzoglou I, Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care 2010;33(7):1523-8
   PubMed Web of Science ®Google Scholar
• Dominguez H, Storgaard H, Rask-Madsen C, Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005;42(6):517-25
   PubMed Web of Science ®Google Scholar
• Gupta-Ganguli M, Cox K, Means B, Does therapy with anti-TNF-alpha improve glucose tolerance and control in patients with type 2 diabetes? Diabetes Care 2011;34(7):e121
   PubMedGoogle Scholar
• Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008;294(4):F697-701
   PubMed Web of Science ®Google Scholar